Enveric Biosciences, Inc.: Form 10-K for the period ended Dec 31, 2014
Filed with the SEC on Mar 31, 2015 and accepted by EDGAR at Mar 31, 2015, 16:12 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2014-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Operating income | 12 months2014-01-01 to 2014-12-31 | $32.8k | us-gaap:OperatingIncomeLoss |
| Income tax | 12 months2014-01-01 to 2014-12-31 | $833 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2014-01-01 to 2014-12-31 | −$33.6k | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2014-01-01 to 2014-12-31 | $0.00 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 12 months2014-01-01 to 2014-12-31 | −$43.2k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2014-12-31 | $5.1k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2014-12-31 | $5.1k | us-gaap:AssetsCurrent |
| Total assets | At period end2014-12-31 | $5.1k | us-gaap:Assets |
| Current liabilities | At period end2014-12-31 | $9.0k | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | At period end2014-12-31 | −$3.9k | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001079974-15-000209. Last ingested by Listed: Nov 14, 2026, 20:02 ET. Listed shows no prices and gives no investment advice.